[go: up one dir, main page]

WO2013153161A3 - Polymorph of rilpivirine hydrochloride - Google Patents

Polymorph of rilpivirine hydrochloride Download PDF

Info

Publication number
WO2013153161A3
WO2013153161A3 PCT/EP2013/057596 EP2013057596W WO2013153161A3 WO 2013153161 A3 WO2013153161 A3 WO 2013153161A3 EP 2013057596 W EP2013057596 W EP 2013057596W WO 2013153161 A3 WO2013153161 A3 WO 2013153161A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorph
present
rilpivirine hydrochloride
novel
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2013/057596
Other languages
French (fr)
Other versions
WO2013153161A2 (en
Inventor
Andreas Hotter
Arthur Pichler
Verena Adamer
Ulrich Griesser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of WO2013153161A2 publication Critical patent/WO2013153161A2/en
Publication of WO2013153161A3 publication Critical patent/WO2013153161A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a novel polymorph and to novel solvates of rilpivirine hydrochloride, as well as to their preparation. The novel solvates are valuable intermediates for the preparation of the novel polymorph of rilpivirine hydrochloride of the present invention. Moreover the present invention relates to the use of the novel polymorph for the preparation of a medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel polymorph of rilpivirine hydrochloride and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel polymorph of rilpivirine hydrochloride and additional therapeutic agents.
PCT/EP2013/057596 2012-04-11 2013-04-11 Novel polymorph of rilpivirine hydrochloride Ceased WO2013153161A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12163720 2012-04-11
EP12163720.1 2012-04-11

Publications (2)

Publication Number Publication Date
WO2013153161A2 WO2013153161A2 (en) 2013-10-17
WO2013153161A3 true WO2013153161A3 (en) 2013-12-05

Family

ID=48050762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/057596 Ceased WO2013153161A2 (en) 2012-04-11 2013-04-11 Novel polymorph of rilpivirine hydrochloride

Country Status (1)

Country Link
WO (1) WO2013153161A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166952B2 (en) 2019-11-29 2021-11-09 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015136294A1 (en) * 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632232A1 (en) * 2004-09-02 2006-03-08 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
WO2012125993A1 (en) * 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
WO2012143937A2 (en) * 2011-04-15 2012-10-26 Emcure Pharmaceuticals Limited An improved rilpivirine process
WO2012147091A2 (en) * 2011-04-25 2012-11-01 Hetero Research Foundation Process for rilpivirine
WO2013038425A1 (en) * 2011-09-16 2013-03-21 Hetero Research Foundation Rilpivirine hydrochloride

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (en) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidines derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632232A1 (en) * 2004-09-02 2006-03-08 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
WO2012125993A1 (en) * 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
WO2012143937A2 (en) * 2011-04-15 2012-10-26 Emcure Pharmaceuticals Limited An improved rilpivirine process
WO2012147091A2 (en) * 2011-04-25 2012-11-01 Hetero Research Foundation Process for rilpivirine
WO2013038425A1 (en) * 2011-09-16 2013-03-21 Hetero Research Foundation Rilpivirine hydrochloride

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166952B2 (en) 2019-11-29 2021-11-09 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer
US11571422B2 (en) 2019-11-29 2023-02-07 Scipio Life Sciences Limited Composition including rilpivirine and method for treating tumors or cancer
US12023334B2 (en) 2019-11-29 2024-07-02 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer

Also Published As

Publication number Publication date
WO2013153161A2 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
WO2012154679A8 (en) Tricyclic pyrazole sulfonamide compounds and methods of making and using same
WO2013004995A8 (en) Pyrimidinone compounds and their use
TN2012000414A1 (en) Forms of rifaximin and uses thereof
EA033544B1 (en) Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
WO2012155066A3 (en) Spiro-oxindole mdm2 antagonists
WO2012032209A3 (en) Pharmaceutical composition for the treatment of dry eye
WO2013158928A3 (en) Chemosensory receptor ligand-based therapies
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
IN2015DN01119A (en)
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
IL223872A (en) Pyrazoloquinolines and intermediate compounds, process for their preparation, use thereof and medicaments and pharmaceutical compositions comprising them
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
ZA201306905B (en) Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these
IL225105A (en) Heterocyclic compounds, process for their preparation, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments
EP2701689A4 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
MX2013006670A (en) 2-carboxamide-4-piperazinyl-benzofuran derivative.
WO2013153161A3 (en) Polymorph of rilpivirine hydrochloride
MX367773B (en) Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof.
MX2013003859A (en) Picropodophyllin polymorphs b or c for use in cancer therapy.
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13714974

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13714974

Country of ref document: EP

Kind code of ref document: A2